Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>BioLineRx is a commercial stage biopharmaceutical company with a development portfolio advancing motixafortide, a platform molecule targeting indications in stem cell mobilization (SCM) & in the treatment of advanced pancreatic cancer.</li><li>The candidate is approved in the US for SCM and is undergoing studies for use in gene therapy and in pancreatic cancer.</li><li>Partner Gloria Biosciences is developing motixafortide in Asia & is expected to be conducting bridging studies in the near term for SCM and longer-term studies for other indications.</li></ul>

BioLineRx is a commercial stage biopharmaceutical company with a development portfolio advancing motixafortide, a platform molecule targeting indications in stem cell mobilization (SCM) & in the treatment of advanced pancreatic cancer.The candidate is approved in the US for SCM and is undergoing studies for use in gene therapy and in pancreatic cancer.Partner Gloria Biosciences is developing motixafortide in Asia & is expected to be conducting bridging studies in the near term for SCM and longer-term studies for other indications.

Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

<p>BioLineRx is currently focused on the development of BL-8040, which is a short peptide antagonist for CXCR4, a chemokine receptor involved with tumor progression, angiogenesis, metastasis and cell survival. BL-8040 is being developed for a variety of solid tumors including pancreatic, gastric and NSCLC. It is also being developed for AML and stem cell mobilization. They are also developing AGI-134, an alpha-gal immunotherapy for solid tumors, which is expected to enter the clinic within 12 months.  BioLineRx has multiple collaborators including Genentech, Merck and Novartis.</p>

BioLineRx is currently focused on the development of BL-8040, which is a short peptide antagonist for CXCR4, a chemokine receptor involved with tumor progression, angiogenesis, metastasis and cell survival. BL-8040 is being developed for a variety of solid tumors including pancreatic, gastric and NSCLC. It is also being developed for AML and stem cell mobilization. They are also developing AGI-134, an alpha-gal immunotherapy for solid tumors, which is expected to enter the clinic within 12 months.  BioLineRx has multiple collaborators including Genentech, Merck and Novartis.

Multiple shots on goal and multiple partners

Israel

BioLineRx Ltd. is a biopharmaceutical development company. The Company develops clinical-stage therapeutic pharmaceutical drugs.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BioLine RX (BLRX US)

BLRX: First Quarter 2024 Results

BioLineRx is a commercial stage biopharmaceutical company with a development portfolio advancing motixafortide, a platform molecule targeting...

Zacks Small Cap Research

Multiple shots on goal and multiple partners

BioLineRx is currently focused on the development of BL-8040, which is a short peptide antagonist for CXCR4, a chemokine receptor involved with...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)